ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Ginkgo Bioworks, a Boston-based cell-programming specialist, will deploy its high-throughput enzyme design and screening technology to help the synthetic biology firm Antheia broaden its pipeline of drug active ingredients and starting materials. Antheia recently raised $73 million to advance its method for making complex molecules in yeast. Meanwhile, Ginkgo and Aldevron say they have made progress in their partnership to optimize Aldevron’s production of messenger RNA vaccine components.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter